Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 28 entries
View as:

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Phase: N/A Priority: Normal
NCT ID: NCT01839097 Org: User:
Start: 05/31/13 End: 01/31/16 Due: 01/31/17

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Phase: N/A Priority: Normal
NCT ID: NCT06072131 Org: User:
Start: 10/04/23 End: 11/30/30 Due: 11/30/31

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00364923 Org: User:
Start: 08/31/06 End: 02/24/09 Due: 02/24/10

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Phase: N/A Priority: Normal
NCT ID: NCT00722553 Org: User:
Start: 07/31/08 End: 09/30/11 Due: 09/30/12

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Phase: N/A Priority: Normal
NCT ID: NCT02594267 Org: User:
Start: 11/10/15 End: 10/08/20 Due: 10/08/21

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Phase: N/A Priority: Normal
NCT ID: NCT04184869 Org: User:
Start: 08/05/19 End: 03/31/23 Due: 03/31/24

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Phase: N/A Priority: Normal
NCT ID: NCT02680795 Org: User:
Start: 04/27/16 End: 07/21/20 Due: 07/21/21

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Phase: N/A Priority: Normal
NCT ID: NCT01110733 Org: User:
Start: 02/28/10 End: 12/31/19 Due: 12/31/20

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00144963 Org: User:
Start: 07/31/02 End: 08/31/06 Due: 08/31/07

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00554827 Org: User:
Start: 08/31/07 End: 02/29/12 Due: 02/28/13

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT07036133 Org: User:
Start: 12/28/22 End: 09/30/27 Due: 09/30/28

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05571943 Org: User:
Start: 09/15/22 End: 07/31/24 Due: 07/31/25

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Phase: N/A Priority: Normal
NCT ID: NCT01851551 Org: User:
Start: 09/30/01 End: 04/30/05 Due: 04/30/06

Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01583777 Org: User:
Start: 09/30/13 End: 04/30/15 Due: 04/30/16

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Phase: N/A Priority: Normal
NCT ID: NCT01789723 Org: User:
Start: 03/31/13 End: 03/31/15 Due: 03/31/16

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Phase: N/A Priority: Normal
NCT ID: NCT05608343 Org: User:
Start: 10/01/22 End: 10/27/23 Due: 10/27/24

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Phase: N/A Priority: Normal
NCT ID: NCT02679131 Org: User:
Start: 03/31/16 End: 06/30/17 Due: 06/30/18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01134341 Org: User:
Start: 03/31/10 End: 08/31/15 Due: 08/31/16

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT01310244 Org: User:
Start: 12/31/10 End: 08/31/15 Due: 08/31/16

PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00925782 Org: User:
Start: 01/31/10 End: 07/31/11 Due: 07/31/12

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00145041 Org: User:
Start: 02/28/05 End: 11/30/07 Due: 11/30/08

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02106650 Org: User:
Start: 07/31/14 End: 06/30/19 Due: 06/30/20

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01118624 Org: User:
Start: 03/31/10 End: 07/31/12 Due: 07/31/13

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Phase: N/A Priority: Normal
NCT ID: NCT01820091 Org: User:
Start: 04/30/13 End: 04/30/15 Due: 04/30/16

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00481871 Org: User:
Start: 05/31/07 End: 08/31/11 Due: 08/31/12